Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | HTR2B | P41595 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | NCF1 | P14598 | 1/20 | 0.31 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18911860 | 0.91 | — | — | |
| SCHEMBL3437026 | 0.91 | TDP1 (0.35) | HTR2AHTR2CHTR2BKDM4ETDP1 | |
| SCHEMBL24185469 | 0.90 | ALDH1A1 (0.30) | — | |
| SCHEMBL15185049 | 0.86 | — | — | |
| SCHEMBL25043777 | 0.86 | HTR2A (0.30) | HTR2AHTR2CHTR2B | |
| SCHEMBL24185168 | 0.86 | KDM4E (0.33) | HTR2AHTR2CHTR2BKDM4ETDP1 | |
| SCHEMBL26743389 | 0.86 | KDM4E (0.33) | HTR2AHTR2CHTR2BKDM4ETDP1 | |
| SCHEMBL20793091 | 0.85 | — | — | |
| SCHEMBL24185555 | 0.85 | — | — | |
| SCHEMBL8439285 | 0.84 | NCF1 (0.41) | HTR2AHTR2CHTR2BKDM4ETDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120157677-A | Bridged-ring organic polyamine, preparation method and application | 大连理工大学 | 2025-06-17 | — | — | CN | disclosed |
| WO-2023220134-A1 | PYRAZINE DERIVATIVES AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| WO-2023220137-A1 | PYRAZINE DERIVATIVES AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| WO-2023220129-A1 | BENZOYPARAZINE PYRAZINES ANE THEIR USES | FOGHORN THERAPEUTICS INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| US-20230295109-A1 | PYRIDINONE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | HOFFMANN-LA ROCHE INC. (US) | 2023-09-21 | — | — | US | disclosed |
| EP-3974423-A1 | INDOLE DERIVATIVE-CONTAINING INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Shanghai Hansoh Biomedical Co., Ltd. (CN) | 2022-03-30 | — | — | EP | disclosed |
| WO-2021133886-A1 | COMBINATIONS OF ESTROGEN RECEPTOR DEGRADERS AND CYCLIN-DEPENDENT KINASE INHIBITORS FOR TREATING CANCER | Accutar Biotechnology (US) | 2021-07-01 | — | — | WO | disclosed |
| WO-2020233669-A1 | INDOLE DERIVATIVE-CONTAINING INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 上海翰森生物医药科技有限公司 (CN) | 2020-11-26 | — | — | WO | disclosed |
| WO-2020150372-A1 | ANTIMICROBIAL COMPOUNDS AND METHODS | CURZA GLOBAL, LLC (US) | 2020-07-23 | — | — | WO | disclosed |
| EP-1403250-B1 | BIS(5-ARYL-2-PYRIDYL) DERIVATIVE | KOWA CO (JP) | 2007-07-18 | — | — | EP | disclosed |
| US-7196101-B2 | Bis(5-aryl-2-pyridyl) compound having excellent immunoglobulin (IgE) antibody production inhibiting activity, useful for the prevention or treatment of allergic immune diseases | KOWA CO., LTD (JP) | 2007-03-27 | — | — | US | disclosed |
| US-7196101-B2 | Bis(5-aryl-2-pyridyl) compound having excellent immunoglobulin (IgE) antibody production inhibiting activity, useful for the prevention or treatment of allergic immune diseases | KOWA CO., LTD (JP) | 2007-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295109-A1 | PYRIDINONE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | PNPO, PDXK, C5 | HTR2A 2759/4885HTR2C 2661/4885HTR2B 1875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.